Regenerx Biopharmaceuticals, Inc.

Michelle Wheater

Allan L Goldstein

Gabriel Sosne

A method of treatment for treating, at least partly preventing, inhibiting or reducing tissue deterioration, injury or damage due to a periodontal disease or disease of oral mucosa, or for restoring tissue adversely affected by the disease, in a subject, and/or for downregulating NF-kappaB or suppressing NF-kappaB mediated action in a body, organ, tissue or cell, includes administering to a subject, body, organ, tissue or cell an effective amount of a composition including a peptide agent including at least one of Thymosin beta 4 (T&#x3b2;4), an isoform of T&#x3b2;4, an N-terminal fragment of T&#x3b2;4, a C-terminal fragment of T&#x3b2;4, T&#x3b2;4 sulfoxide, an LKKTET peptide or conservative variant thereof, an LKKTNT peptide or conservative variant thereof, a KLKKTET peptide or conservative variant thereof, an LKKTETQ peptide or conservative variant thereof, T&#x3b2;4, T&#x3b2;9, T&#x3b2;10, T&#x3b2;11, T&#x3b2;12, T&#x3b2;13, T&#x3b2;14, T&#x3b2;15, gelsolin, vitamin D binding protein (DBP), profilin, cofilin, depactin, DnaseI, vilin, fragmin, severin, capping protein, &#x3b2;-actinin, acumentin, an actin-sequestering peptide, an actin binding peptide, an actin-mobilizing peptide, an actin polymerization-modulating peptide, or a stimulating agent that stimulates production of an effective amount of the peptide agent in the subject, body, organ, tissue or cell.

Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating NF-kappabeta or supressing NF-kappabeta-mediated actions

Growing community of inventors

Warren, MI, United States of America

Michelle Wheater